Breffni Martin

Breffni Martin was educated at St Micheal’s College Dublin and Cistercian College Roscrea. At University College Dublin he received his BSc specialising in biochemistry in 1983. Thereafter he worked for a number of major pharmaceutical companies in the area of late stage drug development, in a scientific, regulatory and information technology context, as well as in environmental management. These include GlaxoSmithKline, Bristol-Myers Squibb, Laboratoire Guerbet and Fermenta (a Pharmacia spin-off).

In 1997 he joined IMS Health (IDRAC, a regulatory intelligence company) where he developed regulatory content covering North America, Japan, Australia and elsewhere, including a dedicated FDA Advisory Committee intelligence business. He subsequently set up and operated Regintel and CanReg (Europe), regulatory intelligence and services companies.  

He is a long-standing member of the DIA and regular Programme Chair, speaker and contributor to DIA’s meetings and publications. He was co-leading the DIA/ISPE CSV workshop recently held in Basel and he served on the DIA Advisory Committee for Europe from 2004 – 2009.